The experimental type 2 diabetes therapy glycogen phosphorylase inhibition can impair aerobic muscle function during prolonged contraction

Diabetes

Volumn 55, Issue 6, 2006, Pages 1855-1861

  Baker, David J ^a   Greenhaff, Paul L ^a   MacInnes, Alan ^b   Timmons, James A ^c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b PFIZER INC   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

GPi, glycogen phosphorylase inhibitors; GPS, gastrocnemius plantaris soleus; HMP, hexosemonophosphate; QOL, quality of life

Indexed keywords

GLUCOSE; GLYCOGEN PHOSPHORYLASE;

AEROBIC EXERCISE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENERGY METABOLISM; GASTROCNEMIUS MUSCLE; GLUCOSE BLOOD LEVEL; MUSCLE CONTRACTION; MUSCLE FATIGUE; MUSCLE FUNCTION; NONHUMAN; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE; SOLEUS MUSCLE;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; FEMALE; GLUCOSE; GLYCOGEN; GLYCOGEN PHOSPHORYLASE; GLYCOGEN PHOSPHORYLASE, LIVER FORM; GLYCOGEN PHOSPHORYLASE, MUSCLE FORM; LACTIC ACID; LIVER GLYCOGEN; MUSCLE CONTRACTION; MUSCLE, SKELETAL; RATS; RATS, WISTAR;

EID: 33748311966     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db05-1687     Document Type: Article

References (49)

1. Ercan-Fang N, Taylor MR, Treadway JL, Levy CB, Genereux PE, Gibbs EM, Rath VL, Kwon Y, Gannon MC, Nuttall FQ: Endogenous effectors of human liver glycogen phosphorylase modulate effects of indole-site inhibitors. Am J Physiol Endocrinol Metab 289:E366-E372, 2005
2. Lerin C, Montell E, Nolasco T, Garcia-Rocha M, Guinovart JJ, Gomez-Foix AM: Regulation of glycogen metabolism in cultured human muscles by the glycogen phosphorylase inhibitor CP-91149. Biochem J 378:1073-1077, 2004
3. Martin WH, Hoover DJ, Armento SJ, Stock IA, McPherson RK, Danley DE, Stevenson RW, Barrett EJ, Treadway JL: Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. Proc Natl Acad Sci U S A 95:1776-1781, 1998
4. Ogawa AK, Willoughby CA, Bergeron R, Ellsworth KP, Geissler WM, Myers RW, Yao J, Harris G, Chapman KT: Glucose-lowering in a db/db mouse model by dihydropyridine diacid glycogen phosphorylase inhibitors. Bioorg Med Chem Lett 13:3405-3408, 2003
5. Al-Khalili L, Forsgren M, Kannisto K, Zierath JR, Lonnqvist F, Krook A: Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma co-activator 1. Diabetologia 48:1173-1179, 2005
6. Kramer DK, Al-Khalili L, Perrini S, Skogsberg J, Wretenberg P, Kannisto K, Wallberg-Henriksson H, Ehrenborg E, Zierath JR, Krook A: Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor δ. Diabetes 54:1157-1163, 2005
7. Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS Jr: Physical activity and reduced occurrence of noninsulin-dependent diabetes mellitus. N Engl J Med 325:147-152, 1991
8. Arad M, Maron BJ, Gorham JM, Johnson WH, Jr, Saul JP, Perez-Atayde AR, Spirito P, Wright GB, Kanter RJ, Seidman CE, Seidman JG: Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 352:362-372, 2005
9. Moller DE: New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414:821-827, 2001
10. Dohrmann CE: Target discovery in metabolic disease. Drug Discov Today 9:785-794, 2004
11. Oikonomakos NG, Schnier JB, Zographos SE, Skamnaki VT, Tsitsanou KE, Johnson LN: Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site. J Biol Chem 275:34566-34573, 2000
12. Tracey WR, Treadway JL, Magee WP, Sutt JC, McPherson RK, Levy CB, Wilder DE, Yu LJ, Chen Y, Shanker RM, Mutchler AK, Smith AH, Flynn DM, Knight DR: Cardioprotective effects of ingliforib, a novel glycogen phosphorylase inhibitor. Am J Physiol Heart Circ Physiol 286:H1177-H1184, 2004
13. Bradley C: Importance of differentiating health status from quality of life. Lancet 357:7-8, 2001
14. Fleg JL, Morrell CH, Bos AG, Brant LJ, Talbot LA, Wright JG, Lakatta EG: Accelerated longitudinal decline of aerobic capacity in healthy older adults. Circulation 112:674-682, 2005
15. Casey A, Short AH, Curtis S, Greenhaff PL: The effect of glycogen availability on power output and the metabolic response to repeated bouts of maximal, isokinetic exercise in man. Eur J Appl Physiol Occup Physiol 72:249-255, 1996
16. Broberg S, Sahlin K: Hyperammoniemia during prolonged exercise: an effect of glycogen depletion? J Appl Physiol 65:2475-2477, 1988
17. Hermansen L, Hultman E, Saltin B: Muscle glycogen during prolonged severe exercise. Acta Physiol Scand 71:129-139, 1967
18. Bergstrom J, Hultman E: Muscle glycogen synthesis after exercise: an enhancing factor localized to the muscle cells in man. Nature 210:309-310, 1966
19. Newgard CB, Hwang PK, Fletterick RJ: The family of glycogen phosphorylases: structure and function. Crit Rev Biochem Mol Biol 24:69-99, 1989
20. Baker DJ, Timmons JA, Greenhaff PL: Glycogen phosphorylase inhibition in type 2 diabetes therapy: a systematic evaluation of metabolic and functional effects in rat skeletal muscle. Diabetes 54:2453-2459, 2005
21. Albright A, Franz M, Hornsby G, Kriska A, Marrero D, Ullrich I, Verity LS: American College of Sports Medicine position stand: exercise and type 2 diabetes. Med Sci Sports Exerc 32:1345-1360, 2000
22. Timmons JA, Larsson O, Jansson E, Fischer H, Gustafsson T, Greenhaff PL, Ridden J, Rachman J, Peyrard-Janvid M, Wahlestedt C, Sundberg CJ: Human muscle gene expression responses to endurance training provide a novel perspective on Duchenne muscular dystrophy. FASEB J 19:750-760, 2005
23. Timmons JA, Jansson E, Fischer H, Gustafsson T, Greenhaff PL, Ridden J, Rachman J, Sundberg CJ: Modulation of extracellular matrix genes reflects the magnitude of physiological adaptation to aerobic exercise training in humans. BMC Biol 3:19, 2005
24. Krustrup P, Ferguson RA, Kjaer M, Bangsbo J: ATP and heat production in human skeletal muscle during dynamic exercise: higher efficiency of anaerobic than aerobic ATP resynthesis. J Physiol 549:255-269, 2003
25. Krustrup P, Soderlund K, Mohr M, Bangsbo J: Slow-twitch fiber glycogen depletion elevates moderate-exercise fast-twitch fiber activity and O2 uptake. Med Sci Sports Exerc 36:973-982, 2004
26. Honig CR, Connett RJ, Gayeski TE: O2 transport and its interaction with metabolism: a systems view of aerobic capacity. Med Sci Sports Exerc 24:47-53, 1992
27. Shulman RG, Rothman DL: The "glycogen shunt" in exercising muscle: a role for glycogen in muscle energetics and fatigue. Proc Natl Acad Sci U S A 98:457-461, 2001
28. Hultman E: Studies on muscle metabolism of glycogen and active phosphate in man with special reference to exercise and diet. Scand J Clin Lab Invest Suppl 94:1-63, 1967
29. Sahlin K, Katz A, Broberg S: Tricarboxylic acid cycle intermediates in human muscle during prolonged exercise. Am J Physiol 259:C834-C841, 1990
30. Baldwin J, Snow RJ, Gibala MJ, Garnham A, Howarth K, Febbraio MA: Glycogen availability does not affect the TCA cycle or TAN pools during prolonged, fatiguing exercise. J Appl Physiol 94:2181-2187, 2003
31. MacInnes A, Timmons JA: Metabolic adaptations to repeated periods of contraction with reduced blood flow in canine skeletal muscle. BMC Physiol 5:11, 2005
32. Harris RC, Marlin DJ, Snow DH, Harkness RA: Muscle ATP loss and lactate accumulation at different work intensities in the exercising Thoroughbred horse. Eur J Appl Physiol Occup Physiol 62:235-244, 1991
33. Dawson KD, Baker DJ, Greenhaff PL, Gibala MJ: An acute decrease in TCA cycle intermediates does not affect aerobic energy delivery in contracting rat skeletal muscle. J Physiol 565:637-643, 2005
34. Gibala MJ: Anaplerosis of the muscle tricarboxylic acid cycle pool during contraction: does size matter? J Physiol 548:334, 2003
35. van Loon LJ, Greenhaff PL, Constantin-Teodosiu D, Saris WH, Wagenmakers AJ: The effects of increasing exercise intensity on muscle fuel utilisation in humans. J Physiol 536:295-304, 2001
36. van Loon LJ, Thomason-Hughes M, Constantin-Teodosiu D, Koopman R, Greenhaff PL, Hardie DG, Keizer HA, Saris WH, Wagenmakers AJ: Inhibition of adipose tissue lipolysis increases intramuscular lipid and glycogen use in vivo in humans. Am J Physiol Endocrinol Metab 289:E482-E493, 2005
37. Pederson BA, Cope CR, Schroeder JM, Smith MW, Irimia JM, Thurberg BL, DePaoli-Roach AA, Roach PJ: Exercise capacity of mice genetically lacking muscle glycogen synthase: in mice, muscle glycogen is not essential for exercise. J Biol Chem 280:17260-17265, 2005
38. Pederson BA, Cope CR, Irimia JM, Schroeder JM, Thurberg BL, Depaoli-Roach AA, Roach PJ: Mice with elevated muscle glycogen stores do not have improved exercise performance. Biochem Biophys Res Commun 331:491-496, 2005
39. Baldwin KM, Reitman JS, Terjung RL, Winder WW, Holloszy JO: Substrate depletion in different types of muscle and in liver during prolonged running. Am J Physiol 225:1045-1050, 1973
40. Aschenbach WG, Suzuki Y, Breeden K, Prats C, Hirshman MF, Dufresne SD, Sakamoto K, Vilardo PG, Steele M, Kim JH, Jing SL, Goodyear LJ, DePaoli-Roach AA: The muscle-specific protein phosphatase PP1G/R (GL)(G(M)) is essential for activation of glycogen synthase by exercise. J Biol Chem 276:39959-39967, 2001
41. Pederson BA, Schroeder JM, Parker GE, Smith MW, Depaoli-Roach AA, Roach PJ: Glucose metabolism in mice lacking muscle glycogen synthase. Diabetes 54:3466-3473, 2005
42. Erion MD, van Poelje PD, Mackenna DA, Colby TJ, Montag AC, Fujitaki JM, Linemeyer DL, Bullough DA: Liver-targeted drug delivery using HepDirect prodrugs. J Pharmacol Exp Ther 312:554-560, 2005
43. Erion MD, van Poelje PD, Dang Q, Kasibhatla SR, Potter SC, Reddy MR, Reddy KR, Jiang T, Lipscomb WN: MB06322 (CS-917): a potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes. Proc Natl Acad Sci U S A 102:7970-7975, 2005
44. Ercan-Fang N, Taylor MR, Treadway JL, Levy CB, Genereux PE, Gibbs EM, Rath VL, Kwon Y, Gannon MC, Nuttall FQ: Endogenous effectors of human liver glycogen phosphorylase modulate effects of indole-site inhibitors. Am J Physiol Endocrinol Metab 289:E366-E372, 2005
45. Timmons JA, Poucher SM, Constantin-Teodosiu D, Macdonald IA, Greenhaff PL: Metabolic responses from rest to steady state determine contractile function in ischemic skeletal muscle. Am J Physiol 273:E233-E238, 1997
46. Timmons JA, Poucher SM, Constantin-Teodosiu D, Macdonald IA, Greenhaff PL: Regulation of skeletal muscle carbohydrate oxidation during steady-state contraction. Am J Physiol 274:R1384-R1389, 1998
47. Harris RC, Hultman E, Nordesjo LO: Glycogen, glycolytic intermediates and high-energy phosphates determined in biopsy samples of musculus quadriceps femoris of man at rest: methods and variance of values. Scand J Clin Lab Invest 33:109-120, 1974
48. Idstrom JP, Soussi B, Wanag E, Bylund-Fellenius AC: Analysis of purine nucleotides in muscle tissue by HPLC. Scand J Clin Lab Invest 50:541-549, 1990
49. Holmes PA, Mansour TE: Glucose as a regulator of glycogen phosphorylase in rat diaphragm: I. Effect of glucose and related compounds on phosphorylase and glycogen levels. Biochim Biophys Acta 156:266-274, 1968